Michael Kuo

Mr. Kuo, MT (ASCP) has more than 24 years of experience in developing novel cell, gene and regenerative medicine therapies to support early - to - late - stage clinical trials. H e previously served as MANA Therapeutics’ Senior Vice President of Technical Operations and Vice President of Quality and Operations at MaxCyte Mr. Kuo also served as Senior Director of Quality Assurance at Mesoblast and held various CMC leadership positions throughout his career. He has established and directed numerous GMP manufacturing, quali ty assurance, and analytical testing operations and provided oversight of clinical manufacturing, process development, translational scale up, technology transfer and analytical testing at major global contract manufacturing and development organizations a nd contract testing laboratories. Mr. Kuo received his BS degrees in Medical Technology and Microbiology as well as his Biomedical Regulatory Affairs Certification from the University of Washington.